The Institute for Clinical and Economic Review (ICER) recently released a Final Evidence Report and Report-at-a-Glance evaluating comparative clinical effectiveness and value of the following targeted immune modulators (TIMs) for moderate-to-severe ulcerative colitis: […]
Reminder: ICER Webinar on Cost-Recovery Pricing for COVID-19 Drugs is Tomorrow
The first installment of the Institute for Clinical and Economic Review's (ICER) three-part webinar series on drug pricing models for COVID-19 treatments is tomorrow, July 24. Set to begin at noon, the webinar will explore cost-recovery pricing, a model used to cover costs associated with […]
First Installment in ICER Webinar Series is Friday
The first session of the Institute for Clinical and Economic Review's (ICER) upcoming webinar series is set for Friday, July 24. ICER is hosting a 3-part colloquium series to complement its recent white paper on alternative approaches for pricing COVID-19 treatments and vaccines. The first […]
ICER Hosting Series on Drug Pricing During a Pandemic
The Institute for Clinical and Economic Review (ICER) is scheduled to host a three-part series focused on drug pricing during a pandemic. The first session, which will discuss cost-recovery pricing, is set for noon EST July 24. Confirmed speakers include: Afton Cissell, JD, Senior Counsel […]
ICER Reschedules CF Meeting
The Institute for Clinical and Economic Review (ICER) has rescheduled its public meeting on cystic fibrosis treatments to Aug. 27. According to a press release, the meeting, which had originally been postponed due to the COVID-19 pandemic, will take place online. To read the full press […]
ICER Outlines Planned Review of High Cholesterol Treatments
The Institute for Clinical and Economic Review (ICER) in a recently-released document outlines its planned review of high cholesterol treatments. ICER's assessment will include Novartis' inclisiran, Esperion Therepeutics' Nexletol and Nexlizet, according to a press release. Comments on the […]
ICER Posts White Paper on Alternative Pricing Policies During Pandemic
The Institute for Clinical and Economic Review (ICER) announced the release of a new white paper on alternative policies for pricing drugs and vaccines during a pandemic. ICER is also set to host a three-part online series in which experts will discuss the advantages and disadvantages of […]
ICER Cancels Meeting for Non-Alcoholic Steatohepatitis Assessment
The Institute for Clinical and Economic Review (ICER) has canceled the August meeting of the Midwest CEPAC. The meeting was set to discuss the effectiveness and value of obeticholic acid for the treatment of non-alcoholic steatohepatitis. "This decision is the result of the Food and Drug […]
Reminder: ICER Accepting Comments on Annual Unsupported Price Increase Assessment
The Institute for Clinical and Economic Review (ICER) is accepting public input on the target drugs for this year's Unsupported Price Increase Assessment. Public feedback will be accepted until July 17. According to ICER, the final report is slated to be posted on Jan. 8, 2021. To read the […]
ICER to Assess Roxadustat for Treatment Anemia in Chronic Kidney Disease
The Institute for Clinical and Economic Review (ICER) announced plans to assess FibroGen's roxadustat for the treatment of anemia in chronic kidney disease. An open input period will remain open until 5 p.m. EST July 15. According to a press release, a document outlining the planned review […]
